AbbVie Clinical Pharmacology Research Unit Information Sheet

The health and safety of volunteers and employees is our priority. We have safety protocols in place to keep the unit as safe as possible.

Rye
M26-089 Group 6
Check In: 10 September 2026 and 14 January 2027

Study drug and design:

AbbVie is testing an investigational drug, which is not approved by the Food and Drug Administration (FDA) or any health authority, and is not currently available on the market. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of multiple subcutaneous doses in adult subjects with obesity.

Minimum Subject Selection Criteria:

YOU *may be eligible to take part in this clinical study if you meet the following conditions:*

- Men and women 18-65 years old.
- Females must be permanently surgically sterile, postmenopausal for 1 year or childbearing potential must agree to contraceptive method required by protocol.
- Average weight for height (BMI 30 to 45).
- No history of unstable or severe cardiovascular disease or congestive heart failure.
- No history of any food or drug sensitivity or allergy.
- No hypersensitivity or allergy to acetaminophen.
- Subject unable to take NSAIDs for any reason.
- No history of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption (e.g., pancreatitis, Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery [except pyloromyotomy for pyloric stenosis during infancy], cholecystectomy, vagotomy, bowel resection, etc.)
- No self-reported change in body weight ≥ 5% within 3 months prior to screening.
- Must not have taken medication for the purpose of treating obesity or diabetes (GLP-1/GIP agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine-based stimulants, methylphenidate) for 180 days prior to study drug administration.
- No previous or planned (during the study period) obesity treatment with surgery or a weight loss device or planned changes in regular dietary consumption.
- No presence or history of diseases associated with impaired calcium homeostasis and/or increased bone turnover (e.g., Paget's disease, osteoporosis, or treatment with antiresorptive agents).
- Must not have been enrolled in an obesity trial within 180 days prior to study drug administration.
- Must not take any medications or herbal remedies or supplements that might interfere with the conduct of the study.
- Must be willing to undergo multiple DEXA scans

- Must not have a recent (within 14 days of initial DEXA scan) or planned x-ray barium, contrast dye, or nuclear medicine test.
- Must not have implants, hardware, devices, or other foreign materials in the measurement area that may interfere with the DEXA scan.
- No presence of foreign bodies, local irritation or infections, active skin diseases, tattoos, and/or scars which may interfere with injection site assessments as determined at Screening.
- No history of major depressive disorder or other severe mood or psychiatric disorders within 2 years of screening.
- No history of drug or alcohol abuse for 6 months.
- Non-user of tobacco- or nicotine- containing products within 90 days prior to study drug administration.
- No vaccination for 4 weeks prior to the first dose of study treatment or at least 4 weeks after the last dose of study treatment.
- No blood loss, blood product donation or blood transfusion 8 weeks prior to study drug administration.

Screening at ACPRU in Grayslake

Screening dates: *(To find out if you are suitable to take part in this clinical study)*

- 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31 August 2026 and 01, 02, 03 September 2026.
- **Additional screening dates may be available**.
- Screening appointments are between the hours of 7:00 a.m. and 11:00 a.m. and take approximately 3 hours.

Stipend:

- **Screening:** $75.00 (No compensation if urine drug/alcohol/cotinine screen is positive or if BMI is out of range.)
- **Study:** Compensation of up to $17,005.00 may be provided if selected and you complete the study.

Study dates: *(Please note that these dates and times are subject to change)*

Must complete all periods and/or follow up visit(s).
CHECK IN: 10 September 2026 and 14 January 2027 at scheduled appointment time.
CHECK OUT: 11 September 2026 and 19 January 2027 upon completion of all study procedures and discharge by Principal Investigator.
FOLLOW UP VISITS: Day 15, 29, 43, 57, 71, 85, 99, 113, 134, 141, 155, 187 at scheduled appointment time.
(A follow up visit may be required for safety. If this occurs, you will be notified and compensated for your visit time and travel.)

(Please note that these dates and times are subject to change)

Please call our recruiting office at 1-800-827-2778 to schedule an appointment.